Liu, Zhuohao
Zhou, Jiayi
Yang, Xinzhi
Liu, Yuchen
Zou, Chang
Lv, Wen
Chen, Cheng
Cheng, Kenneth King-yip
Chen, Tao
Chang, Lung-Ji
Wu, Dinglan
Mao, Jie
Funding for this research was provided by:
National Natural Science Foundation of China (81900801, 81872283)
Shenzhen Science and Technology Innovation Program (JCYJ20190814114403618, JCYJ20180508163203807, JCYJ20220530152614033)
Article History
Received: 17 November 2022
Accepted: 29 December 2022
First Online: 9 January 2023
Declarations
:
: This single-center, open-label phase 1 clinical trial was approved by the Clinical Research Committee and Human Ethics Committees of Shenzhen Hospital Southern Medical University and Shenzhen Geno-Immune Medical Institute. All procedures involving human participants were performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from the patients or guardians before enrollment in the study.
: Not applicable.
: The authors declare no potential conflicts of interest.